Cholelithiasis ascomorbidity polycystic ovary syndrome disease

Cover Page

Cite item

Full Text

Abstract

Polycystic ovary syndrome (PCOS) is a complex interdisciplinary problem in connection with the involvement in the pathogenesis not only of reproductive system, but also multifaceted metabolic disorders, many of which are pathognomonic for cholelithiasis. Presented in the article the literature and their own clinical observation suggest predisposing role in the development of PCOS cholelithiasis. Hormonal contraceptives greatly increase the risk of gallstone disease, and may be the trigger of stone formation. The individualized approach to the appointment of COC patients with PCOS with the additional risk of cholelithiasis, and dynamic monitoring would prevent the onset and progression of cholelithiasis.

About the authors

Yu. B Uspenskaya

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: jusp@mail.ru
канд. мед. наук, вед. науч. сотр. НИО женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trube- tskaia, d. 8, str. 2

I. V Kuznetsova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., гл. науч. сотр. НИО женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trube- tskaia, d. 8, str. 2

References

  1. Герок В., Блюм Х.Е. Заболевания печени и желчевыделительной системы. Пер. с нем. Под общ. ред. В.Т.Ивашкина, А.А.Шептулина. М.: МЕДпресс - информ, 2009
  2. Иванченкова Р.А. Хронические заболевания желчевыводящих путей. М.: Атмосфера, 2006.
  3. Ильченко А.А. Классификация желчнокаменной болезни. Тер. архив. 2004; 2: 75-9.
  4. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-МЕД, 2001.
  5. Руководство по амбулаторно - поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014
  6. Руководство по репродуктивной медицине. Под ред. Б.Карра, Р.Блэкуэлла, Р.Азиза. Пер. с англ. М.: Практика, 2015.
  7. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221-9.
  8. Acién P, Quereda F, Matallín P et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32-40.
  9. Barber T.M, Mc Carthy M.I, Wass J.A, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2): 137-45.
  10. Barber T.M, Wass J.A, Mc Carthy M.I, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo - amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66 (4): 513-7.
  11. Basdevant A. Steroids and lipid metabolism: Mechanism of action. Int J Fertil 1992; 37 (Suppl. 2): 93-7.
  12. Bennion, L.J, Grundy S.M. Effects of diabetes mellitus on cholesterol metabolism in man. N Eng J Med 1977; 296: 1365-71.
  13. Coviello A.D, Legro R.S, Dunaif A: Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91: 492-7.
  14. Cryer A. Comparative biochemistry and physiology of lipoprotein lipase. In: Borensztajn J (ed.) Lipoprotein lipase Evener: Chicago, IL, 1987; p. 277-327.
  15. Diehl A.K. Cholelithiasis and the insulin resistance syndrome. Hepatology 2000; 31: 528-30.
  16. Ding E.L, Song Y, Malik V.S, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta - analysis. JAMA 2006; 295: 1288-99.
  17. Duan L.P, Wang H.H, Ohashi A, Wang D.Q-H. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol 2006; 290: G269-G276.
  18. El-Mazny A, Abou-Salem N, El-Sherbiny W. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239-41.
  19. Freeman R, Pollack R, Rosenbloom E. Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 2010; 16 (5): 810-7.
  20. Gielkens H.A, Lam W.F, Coenraad M et al. Effect of insulin on basal and cholecystokinin - stimulated gallbladder motility in humans. J Hepatology 1998; 28: 595-602.
  21. Gilat T, Konikoff F. Pregnancy and the biliary tract. Can J Gastroenterol 2000; 14-37.
  22. Hahm J.S, Park J.Y, Park K.G et al. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 1996; 91: 2391-4.
  23. Isik S, Ozcan H.N, Ozuguz U et al. Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76 (3): 373-8; doi: 10.1111/j.1365-2265.2011.04210.x
  24. Kline L.W, Karpinski E. Progesterone inhibits gallbladder motility through multiple signaling pathways. Steroids 2005; 70 (9): 673-9.
  25. Kline L.W, Karpinski E. Testosterone and dihydrotestosterone inhibit gallbladder motility through multiple signaling pathways. Steroids 2008; 73: 1174-80.
  26. Ko C.W, Beresford S.A, Schulte S.J. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41 (2): 359-65.
  27. Lundholm L, Zang H, Hirschberg A.L et al. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril 2008; 90: 44-8.
  28. Luque-Ramírez M, Alpañés M, Escobar-Morreale H.F. The determinants of insulin sensitivity, b - cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010; 94: 2214-21.
  29. Mendez-Sanchez N, Vega, H, Uribe M et al. Risk factors for gallstone disease in Mexicans are similar to those found in Mexican-Americans. Digest Dis Sci 1998; 43: 935-9.
  30. Nakeeb A, Comuzzie A.G, Al-Azzawi H et al. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006; 10: 940-8.
  31. Ness G.C, Chambers C.M. Feedback and hormonalregulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8-19.
  32. Ness G.C, Zhao Z, Wiggins L. Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutaryl - coenzyme A reductase activity by affecting immunoreactive protein levels. J Biol Chem 1994; 269: 29168-72.
  33. Pesant M.H, Baillargeon J.P: Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011; 95: 210-5.
  34. Philipp B.W, Shapiro D.J. Estrogen regulation of hepatic3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922-7.
  35. Ruhl C.E, Everhart J.E. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31: 299-303.
  36. Sacks F.M, Walsh B.W. The effects of reproductive hormones on serum lipoproteins: Unresolved issues in biology and clinical practice. Multidisciplinary perspectives on menopause. Ann N Y Acad Sci 1990; 592: 272-85.
  37. Simon J.A, Donald B, Hunninghake M.D et al. Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135 (7): 493-501.
  38. Sirmans S.M, Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13; doi: 10.2147/CLEP.S37559
  39. Strom B.L, Tamragouri R.N, Morse M.L et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335-41.
  40. Wild R.A. The PCO paradigm: sex steroids, lipoprotein lipids, clotting, and the arterial wall. In The Ovary: Regulation, Dysfunction and Treatment. M Filicori and C Flamigni, eds. Elsevier Science B.V., 1996; p. 201-9.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies